Skip to main content

Table 7 Regression models of the association of metformin and frailty

From: Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes

Variable

OR

95% CI

P value

Age

4.295

0.970–19.009

0.055

CAD

1.926

1.111–3.339

0.020

CKD

2.129

1.062–4.265

0.033

Stroke

2.875

1.560–5.298

0.001

Osteoarthritis

2.032

1.111–3.719

0.021

Cancer

3.345

1.686–6.638

0.001

PVD

2.148

1.111–4.154

0.023

Metformin

0.564

0.321–0.991

0.047

Constant

0.024

 

0.000

  1. Adjusted by age, sex, duration, FPG, HbA1c, PVD, DR, DPN, hypertension, CAD, COPD, CKD, stroke, osteoarthritis, cancer, and polypharmacy. Sex, hypertension, COPD, duration, FPG, HbA1c, DR, DPN, and polypharmacy were not included in the equation
  2. FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; BMI, body mass index; PVD, peripheral vascular disease; DR, diabetic retinopathy; DPN, diabetic peripheral neuropathy; CAD, coronary atherosclerotic heart disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease